全文获取类型
收费全文 | 79624篇 |
免费 | 5839篇 |
国内免费 | 256篇 |
专业分类
耳鼻咽喉 | 911篇 |
儿科学 | 2046篇 |
妇产科学 | 1084篇 |
基础医学 | 10756篇 |
口腔科学 | 843篇 |
临床医学 | 8442篇 |
内科学 | 17056篇 |
皮肤病学 | 885篇 |
神经病学 | 7813篇 |
特种医学 | 3063篇 |
外科学 | 12812篇 |
综合类 | 888篇 |
一般理论 | 91篇 |
预防医学 | 5959篇 |
眼科学 | 1974篇 |
药学 | 5372篇 |
中国医学 | 95篇 |
肿瘤学 | 5629篇 |
出版年
2024年 | 55篇 |
2023年 | 667篇 |
2022年 | 1042篇 |
2021年 | 2414篇 |
2020年 | 1360篇 |
2019年 | 2209篇 |
2018年 | 2531篇 |
2017年 | 1804篇 |
2016年 | 1895篇 |
2015年 | 2217篇 |
2014年 | 3213篇 |
2013年 | 4062篇 |
2012年 | 6517篇 |
2011年 | 6756篇 |
2010年 | 3694篇 |
2009年 | 3235篇 |
2008年 | 5393篇 |
2007年 | 5591篇 |
2006年 | 5184篇 |
2005年 | 5139篇 |
2004年 | 4638篇 |
2003年 | 4253篇 |
2002年 | 3852篇 |
2001年 | 598篇 |
2000年 | 397篇 |
1999年 | 569篇 |
1998年 | 788篇 |
1997年 | 589篇 |
1996年 | 477篇 |
1995年 | 431篇 |
1994年 | 400篇 |
1993年 | 400篇 |
1992年 | 254篇 |
1991年 | 203篇 |
1990年 | 181篇 |
1989年 | 167篇 |
1988年 | 162篇 |
1987年 | 132篇 |
1986年 | 134篇 |
1985年 | 146篇 |
1984年 | 184篇 |
1983年 | 152篇 |
1982年 | 237篇 |
1981年 | 232篇 |
1980年 | 164篇 |
1979年 | 94篇 |
1978年 | 114篇 |
1977年 | 99篇 |
1976年 | 69篇 |
1975年 | 59篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
41.
Andrew M Briggs John D Wark Susan Kantor Rayson Teh Alison M Greig Nicola L Fazzalari Kim L Bennell 《Journal of clinical densitometry》2005,8(3):314-319
Analysis of apparent bone mineral density (BMD) in the lumbar spine is commonly based on anteroposterior (AP) scanning using dual-energy X-ray absorptiometry (DXA). Although not widely used, clinically important information can also be derived from lateral scanning. Vertebral bone density, and therefore strength, can may vary in different subregions of the vertebral body. Therefore, subregional BMD measurements might be informative about fracture risk. However, the intrarater and interrater precision of in vivo subregional BMD assessments from lateral DXA remains unknown. Ten normal, young (mean: 24 yr) and 10 older (mean: 63 yr) individuals with low BMD were scanned on one occasion using an AP/lateral sequence. Each lateral scan was reanalyzed six times at L2 by three raters to determine the intrarater and interrater precision in selecting seven regions of interest (subregions). Precision was expressed using percentage coefficients of variation (% CV) and intraclass correlation coefficients (ICC). Intrarater precision ranged from ICC(1,1) 0.971 to 0.996 (% CV: 0.50-3.68) for the young cohort and ICC(1,1) 0.934 to 0.993 (% CV: 1.46-5.30) for the older cohort. Interrater precision ranged from ICC(2,1) 0.804 to 0.915 (% CV: 1.11-2.35) for the young cohort and ICC(2,1) 0.912 to 0.984 (% CV: 1.85-4.32) for the older cohort. Scanning a subgroup of participants twice with repositioning was used to assess short-term in vivo precision. At L2, short-term in vivo precision ranged from ICC(1,1) 0.867 to 0.962 (% CV: 3.38-9.61), at L3 from ICC(1,1) 0.961 to 0.988 (% CV: 2.02-5.57) and using an L2/L3 combination from ICC(1,1) 0.942 to 0.980 (% CV: 2.04-4.61). This study demonstrated moderate to high precision for subregional analysis of apparent BMD in the lumbar spine using lateral DXA in vivo. 相似文献
42.
OBJECTIVE: To establish if there is a role for gabapentin or nortriptyline in the treatment of chronic orchialgia. METHODS: Twenty-six consecutive patients with chronic orchialgia were seen in the chronic pain clinic by a multidisciplinary team. A pain questionnaire was completed prior to commencing either gabapentin or nortriptyline. They were reviewed at 3 months and a repeat questionnaire completed. A 50% improvement in pain was considered successful. RESULTS: Complete data was available for 19 patients. Overall, 61.5% of patients commenced on gabapentin and 66.6% of patients commenced on nortriptyline had a greater than 50% improvement in pain. Patients with post-vasectomy testicular pain were considered as a subgroup. None of these patients had a greater than 50% improvement in pain. However, 80% of patients in the subgroup with idiopathic chronic orchialgia had a greater than 50% improvement in pain. CONCLUSION: Although this is a small study, it appears that gabapentin and nortriptyline are effective in the treatment of idiopathic chronic orchialgia but not post-vasectomy pain. 相似文献
43.
44.
This case describes a rare complication of prostaglandin analogue eye drops used for treatment of primary open angle glaucoma. Though increase in the number, size and pigmentation of eyelashes is well‐known, this case shows extensive hair growth in malar region, which can be unacceptable. This complication can be one of the causes of discontinuation of prostaglandin analogue therapy. 相似文献
45.
46.
47.
A. Robert Spitzer Shalom Stahl David Yarnitsky Ernest W. Johnson John R. Wilson R. A. C. Hughes Stefania Morino Giovanni Antonini Kiyotoshi Kaneko Yoji Ohnishi Tetsushi Atsumi Isao Hozumi Tadashi Miyatake Tetsuo Furukawa James P. Knochel Ikuo Mineo Seiichiro Tarui Francis O. Walker Andrew J. Gitter Walter C. Stolov Nicholas J. Capozzoli 《Muscle & nerve》1996,19(4):531-538
48.
K. Hamano Hiroshi Ito Andrew Bushell Kathryn J. Wood Kensuke Esato 《Transplant international》1997,10(4):293-298
In this study, the effect of combining anti-CD4 monoclonal antibody (mAb) and cyclosporin (CyA) therapy at the time of transplantation
was examined. A mouse cardiac allograft model was used. Anti-CD4 mAb administered perioperatively induces long-term survival.
The addition of a short course of CyA given subcutaneously in a regimen of either a high-dose treatment or a standard dose
treatment to the anti-CD4 mAb treatment protocol did not have a detrimental effect on graft survival. Despite having no significant
effect on graft survival, the addition of CyA to the treatment protocol did result in a significant decrease in the level
of IL-2 present in the hearts 7 days after transplantation. The decrease in IL-2 production was directly related to the presence
of CyA in vivo. When CyA treatment was continued throughout the period during which unresponsiveness to the graft is induced
by anti-CD4 mAb therapy, 50 % of the grafted hearts were rejected once the CyA was discontinued. In conclusion, the combined
use of anti-CD4 mAb therapy and CyA did not have a negative effect on graft survival in this model when the two agents were
used concurrently at the time of transplantation.
Received: 2 October 1996 Received after revision: 31 January 1997 Accepted: 5 February 1997 相似文献
49.
50.
Dr. Andrew G. Bostom M.D. Dr. Anne L. Hume Pharm.D. Dr. Charles B. Eaton M.D. Dr. Joseph P. Laurino Ph.D. Ms. Lisa R. Yanek B.A. Ms. Mary S. Regan B.S. Mr. William H. McQuade M.P.H. Dr. Wendy Y. Craig Ph.D. Ms. Gayle Perrone M.B.A. Dr. Paul F. Jacques Sc.D. 《Pharmacotherapy》1995,15(4):458-464
Study Objective . To determine the efficacy of high-dose ascorbate supplementation in lowering lipoprotein(a) [Lp(a)] levels in patients with premature coronary heart disease (CHD). Design . Randomized, double-blind, placebo-controlled trial. Setting . Outpatient clinic. Patients . Forty-four patients with documented premature CHD. defined as confirmed myocardial infarction and/or angiographically determined stenosis of 50% or greater in at least one major coronary artery before age 60 years. Interventions . Patients were block randomized on the basis of age, gender, and screening Lp(a) concentrations to receive ascorbate 4.5 g/day or placebo for 12 weeks. Measurements and Main Results . High-dose ascorbate was well tolerated and produced a marked elevation in mean plasma ascorbate levels (+1.2 mg/dl; p<0.001). Multiple linear regression analysis revealed no significant effect of supplementation on postintervention Lp(a) levels (p=0.39) in a model that included treatment group assignment, and baseline Lp(a) levels. Conclusions . Our findings do not support a clinically important lowering effect of high-dose ascorbate on plasma Lp(a) in patients with premature CHD. 相似文献